Somatic Mutations and Alzheimer's Disease

Area of Science:

• Neuroscience
• Genetics
• Computational Biology

Background:

• Alzheimer's disease (AD) affects 55 million globally, characterized by amyloid-β plaques and tau tangles.
• While proteinopathy is key, diverse genomic regions and aging contribute significantly to AD neurodegeneration.
• Accumulating somatic mutations with age, a major AD risk factor, are increasingly implicated in disease initiation.

Purpose of the Study:

• To review principal genetic factors in Alzheimer's disease pathogenesis.
• To highlight the contribution of somatic mutations to late-onset AD.
• To explore the role of AI and big data in biomarker discovery and drug repurposing for AD.

Main Methods:

• Review of current scientific literature on Alzheimer's disease genetics.
• Analysis of recent research correlating somatic brain mutations with tauopathy progression.
• Discussion of artificial intelligence and big data applications in neurodegenerative disease research.

Main Results:

• Evidence suggests somatic mutations accumulate with aging and correlate with tauopathy progression in the brain.
• Diverse genetic factors, beyond amyloid-β and tau, contribute to AD neurodegeneration.
• AI and big data show promise for identifying causal somatic mutation biomarkers and accelerating drug discovery.

Conclusions:

• Somatic mutations represent a significant, yet under-explored, factor in the pathogenesis of late-onset Alzheimer's disease.
• Targeting somatic mutations offers a potential new avenue for AD therapeutic strategies.
• AI and big data are crucial for advancing our understanding and treatment of AD and other neurodegenerative diseases.